Program

Please be aware that the conference schedule is subject to change without prior notice. We recommend checking this page and our official channels for updates.

Download Schedule

Schedule

Day 1 - Friday, March 28, 2025

Time	Title	Speaker
8:00 AM	BREAKFAST AND REGISTRATION
9:00 AM	Introduction from conference organizers
9:05 AM	Opening remarks	Michael Teitell, MD, PhD University of California, Los Angeles
	PSMA imaging session 1
9:10 AM	History of PSMA	Martin Pomper, MD, PhD University of Texas, Southwestern
9:20 AM	Landscape of approved PSMA imaging agents: does it matter?	Amir Iravani, MD University of Washington
9:30 AM	Pictorial Atlas of PSMA PET	Matthias Benz, MD University of California, Los Angeles
9:40 AM	Impact of clinical guidelines on the utilization of PSMA PET	Emmanuel Antonarakis, MD University of Minnesota
9:50 AM	Panel discussion
	PSMA imaging session 2
10:00 AM	The changing role of MRI in staging patients with prostate cancer	Steven Raman, MD University of California, Los Angeles
10:10 AM	PRIMARY score and where it plays a role	Michael Hofman, FRACP, MBBS Peter MacCallum Cancer Centre, Melbourne, Australia
10:20 AM	PSMA PET fusion guided biopsy	Wayne Brisbane, MD University of California, Los Angeles
10:30 AM	Role of PSMA PET in surgical planning and post-operative management	Carissa Chu, MD University of California, San Francisco
10:40 AM	Panel discussion
10:50 AM	COFFEE BREAK
	PSMA imaging session 3
11:00 AM	Development of upcoming and promising new PSMA imaging agents	Wolfgang Fendler, MD University Hospital Essen, Germany
11:10 AM	WB PSMA quantitative parameters: why are we not using WB PSMA PET parameters in the real world	Irene Buvat, PhD Institut Curie, Orsay, France
11:20 AM	Panel discussion
	PSMA imaging session 4
11:30 AM	Who benefits from oligo-metastases directed therapy?	Julian Hong, MD, MS University of California, San Francisco
11:40 AM	Can we kill the bone scan?	Daniel Spratt, MD University Hospitals, Cleveland, OH
11:50 AM	How to crush a PSMA PET report: guidelines and scoring systems	Phillip Kuo, MD, PhD City of Hope, Los Angeles
12:00 PM	Incorporating PSMA PET into trial endpoints. PCWG4 updates	Michael Morris, MD Memorial Sloan Kettering, New York
12:10 PM	Panel discussion + mini tumor board 1 [PET imaging]
12:40 PM	LUNCH BREAK
	LuPSMA therapy session 1
1:25 PM	Path to Clinical Use: Lesson from compassionate use in Germany	Wolfgang Fendler, MD University Hospital Essen, Germany
1:35 PM	Post-VISION: Real world experience in the US, how is PSMA RLT being used?	Matthew Rettig, MD University of California, Los Angeles
1:45 PM	Radiation Safety and Ecology: Comparison of practices across the US and the world	Catherine Meyer, PhD University of California, Los Angeles
1:55 PM	Panel discussion
	LuPSMA therapy session 2
2:05 PM	How are we getting paid Theranostics?	Denise Merlino, CPC, MBA, CNMT Merlino Healthcare Consulting, Florida
2:15 PM	PSMA RLT in a Medical Oncology private center	Luke Nordquist, MD Xcancer, Omaha, NE
2:25 PM	PSMA RLT in a Radiation Oncology private center	Dustin Boothe, MD Intermountain Health, Salt Lake City, UT
2:35 PM	Patient Experience	TBD
2:45 PM	Panel discussion
	LuPSMA therapy session 3
2:55 PM	Pre-chemo trials: PSMAfore/SPLASH/ECLIPSE	Emmanuel Antonarakis, MD University of Minnesota
3:05 PM	Moving into the castration sensitive setting	Michael Morris, MD Memorial Sloan Kettering Cancer Center
3:15 PM	PSMA RLT for oligometastatic disease	Amar Kishan, MD University of California, Los Angeles
3:25 PM	Overview of enrolling Phase 2/3 trials	Jeremie Calais, MD, PhD University of California, Los Angeles
3:35 PM	Panel discussion
3:45 PM	COFFEE BREAK
	LuPSMA therapy session 4
3:55 PM	When should we use FDG PET?	Andrei Iagaru, MD Stanford University, California
4:05 PM	What’s the best way to evaluate response: SPECT vs PSMA PET?	Thomas Hope, MD University of California, San Francisco
4:15 PM	Moving beyond 6x6	Matthias Eiber, MD, PhD Technische Universität München, Germany
4:25 PM	Treatment Sequencing	Tanya Barauskas Dorff, MD City of Hope, Los Angeles
4:35 PM	Panel discussion + mini tumor board 2 [PSMA RLT]
5:25 PM	Wrap up for the day
5:30 PM	Poster power pitches
5:45 PM	Poster session reception
6:30 PM	Poster awards

Day 2 - Saturday, March 29, 2025

Time	Title	Speaker
8:00 AM	BREAKFAST
	Dosimetry Session 1
9:00 AM	Are we underdosing?	Amir Iravani, MD University of Washington
9:10 AM	Lessons from radiation oncology: How can we improve PSMA RLT?	Daniel Spratt, MD University Hospitals, Cleveland, OH
9:20 AM	“Beyond the 23 Gray threshold”	Ana Ponce Kiess, MD, PhD Johns Hopkins University, Baltimore, MD
9:30 AM	How to use quantitative dosimetry and act on it to adapt treatment	Carlos Uribe, PhD,MCCPM BC Cancer, University of British Columbia
9:40 AM	AI for Dosimetry	Irene Buvat, PhD Institut Curie, Orsay, France
9:50 AM	Let’s get paid for Dosimetry	Denise Merlino, CPC, MBA, CNMT Merlino Healthcare Consulting, Florida
10:00 AM	Panel discussion
	Antibody and other Ligands Session
10:10 AM	PSMA-I&T vs PSMA-617: is there a difference	Matthias Eiber, MD, PhD Technische Universität München, Germany
10:20 AM	Role of PSMA targeted antibodies	Scott Tagawa, MD, MS Weill Cornell Medicine, New York
10:30 AM	Next generation PSMA radioligands	Martin Pomper, MD, PhD University of Texas, Southwestern
10:40 AM	Panel discussion
10:50 AM	COFFEE BREAK
	Alpha and Other Radionuclides Session
11:00 AM	How PSMA RLT kills the cells? Alpha vs beta radiobiology	Ana Ponce Kiess, MD, PhD Johns Hopkins University, Baltimore, MD
11:10 AM	Ac225 PSMA experience	Alfred Morgenstern, PhD Joint Research Centre, Karlsruhe, Germany
11:20 AM	Management of dry mouth	Sue Yom, MD, PhD University of California, San Francisco
11:30 AM	Pb212 PSMA vs Ac225 PSMA: from biology to supply	Alfred Morgenstern, PhD Joint Research Centre, Karlsruhe, Germany
11:40 AM	Role for other radionuclides: Tb161	Michael Hofman, FRACP,MBBS Peter MacCallum Cancer Centre, Australia
11:50 AM	Panel discussion
	PSMA-targeted Non-RPT Session
12:00 PM	CAR-T and Bispecific Antibodies targeting PSMA	Tanya Barauskas Dorff, MD City of Hope, Los Angeles
12:10 PM	Role of ADCs in prostate cancer	John Shen, MD University of California, Los Angeles
1:40 PM	Value of animal models in evaluating RLT	Tanya Stoyanova, PhD University of California, Los Angeles
12:20 PM	Panel discussion	Tanya Barauskas Dorff, MD Matthew Rettig, MD John Shen, MD Tanya Stoyanova, PhD Scott Tagawa, MD, MS
12:30 PM	LUNCH BREAK
	Keynote lecture
1:30 PM	Improving outcomes with combination therapy	Michael Hofman, FRACP,MBBS Peter MacCallum Cancer Centre, Australia
1:50 PM	Panel discussion
	New Developments in GU Radioligand Therapy
2:00 PM	GRPR and other peptides for targeting prostate cancer	Andrei Iagaru, MD Stanford University, California
2:10 PM	DLL3, CD46, STEAP1 and others	Robert Flavell, MD, PhD University of California, San Francisco
2:20 PM	HK2 and HK3 experience	David Ulmert, MD University of California, Los Angeles
2:30 PM	CA-IX in renal cell cancer	Brian Shuch, MD University of California, Los Angeles
2:40 PM	Opportunity for RLT in bladder cancer	Vadim Koshkin, MD University of California, San Francisco
2:50 PM	Panel discussion
3:00 PM	Closing comments